Olympus Corporation receives FDA warning over six facilities
The Oct. 7 letter addresses quality-system responses, while Olympus says it brings no new production or distribution restrictions.
Adrian Kessler
A new compliance response is planned within 15 business days of receipt after Olympus Corporation TYO7733 disclosed an FDA warning letter covering six facilities on Tuesday.
The Oct. 13 announcement says the letter is dated Oct. 7 and follows inspections conducted in late 2025. Olympus says it addresses quality management systems and related processes, without imposing new manufacturing or distribution restrictions.
Olympus is a Japanese medical-technology group supplying equipment for early detection, diagnosis and minimally invasive treatment worldwide.
Shares traded at ¥1,780 in Tokyo on Wednesday, according to the Tokyo Stock Exchange feed on Olympus's investor page at 11:00 a.m. JST. Olympus says it expects no impact on consolidated financial results, with its next earnings report scheduled for Nov. 10.
The exchange disclosure says the warning concerns the adequacy of Olympus's comprehensive responses to observations previously recorded in inspection forms known as Form 483s. Olympus says it has already implemented significant corrective and preventive actions to address the FDA's feedback. The warning concerns how the company responded to earlier inspection observations, with Olympus still promising another response to the agency.
The sites are Olympus Medical Systems Corporation's Hachioji and Hinode facilities, plus Aomori Olympus Co., Ltd. and Shirakawa Olympus Co., Ltd. in Japan. Olympus Winter & IBE GmbH in Hamburg, Germany, and Gyrus ACMI, Inc. in Brooklyn Park, United States, complete the list.
Neither Oct. 13 disclosure identifies individual product models covered by the new letter. The underlying FDA letter was not read for this report, so the company's account provides the available description of its scope.
Olympus says the letter neither requires product recalls nor restricts its ability to seek FDA clearance for new products through the 510(k) pathway. It also says customers need take no additional action and that products remain safe and effective when used according to their instructions.
"Since the inspections concluded in late 2025, we have worked diligently to implement comprehensive corrective and preventive actions," Olympus president and chief executive Bob White said in the Oct. 13 release.
Olympus also describes a comprehensive, multi-year quality system transformation program intended to strengthen global operations. The Oct. 13 release gives no estimate of the cost of completing the remaining work.
Read more: Canopy Growth gains EU GMP certification for Smiths Falls softgels
Olympus plans periodic updates until the FDA determines that its actions are adequate. The disclosures give no receipt date, preventing a calendar deadline from being established for the promised response.
The FDA Previously Announced Import Restrictions
The company's account of the new letter sits alongside a separate FDA notice dated June 24, 2025. That notice announced import alerts intended to prevent future shipments of certain Olympus devices from entering the United States over outstanding quality-system violations.
The FDA identified specific models of ureterorenoscopes, bronchoscopes, laparoscopes and automated endoscope reprocessors. Its recommendations named the Aizu manufacturing site, which is absent from the facilities Olympus lists for the new warning.
Listed Device Makers Reported Sales Growth
The endoscopy market comparison includes Boston Scientific Corporation NYSEBSX, which reported its second-quarter results on July 29. Endoscopy sales reached US$793 million in that quarter, up 7.6 per cent on a reported basis.
The broader device-sector comparison includes Johnson & Johnson NYSEJNJ, whose Oct. 13 results put third-quarter MedTech sales at US$8.642 billion. Reported growth was 2.5 per cent, driven by electrophysiology, Shockwave, contact lenses and trauma products.
Read more: Johnson & Johnson raises 2026 outlook after US$25.4B quarterly sales
Olympus will report second-quarter fiscal 2027 results on Nov. 10. The earnings release will provide a new financial benchmark while Olympus pursues the FDA's acceptance of its corrective actions.
